NCT03791814 A Prospective Cohort Study to Improve HCV Care in Dialysis Patients Status WITHDRAWN Phase PHASE4
NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT03783078 Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Status COMPLETED Phase PHASE3
NCT03776136 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) Status COMPLETED Phase PHASE2
NCT03775850 A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Status COMPLETED Phase PHASE1
NCT03769467 Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) Status TERMINATED Phase PHASE1/PHASE2
NCT03765918 Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03761914 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Status COMPLETED Phase PHASE1/PHASE2
NCT03756454 Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery. Status TERMINATED Phase PHASE4
NCT03755973 Effect of Different Ovarian Stimulation Protocols on Endometrial Receptivity Status COMPLETED Phase PHASE4
NCT03753243 Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer Status UNKNOWN Phase PHASE2
NCT03752723 Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) Status COMPLETED Phase PHASE1/PHASE2
NCT03747120 Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03745989 Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) Status COMPLETED Phase PHASE1
NCT03744637 A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) Status COMPLETED Phase PHASE1
NCT03742895 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) Status ACTIVE_NOT_RECRUITING Phase PHASE2